Navigation Links
Mayo Clinic Proceedings reviews deep brain stimulation to treat psychiatric diseases
Date:6/29/2009

ROCHESTER, Minn. Pioneering therapeutic trials to investigate the effectiveness of deep brain stimulation (DBS) in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the world, according to a review in the June 2009 issue of Mayo Clinic Proceedings. "Deep brain stimulation has long been seen as valuable for controlling movement disorders," according to the review, written by Susannah Tye, Ph.D., Mark Frye, M.D., from the Mayo Clinic Department of Psychiatry and Psychology, and Kendall Lee, M.D., Ph.D., Mayo Clinic Department of Neurosurgery. "It now is being investigated for hard-to-treat psychiatric disorders," according to the authors.

"Early results indicate the effect on depression and obsessive compulsive disorder is beneficial, but the therapy needs further study," Dr. Lee says. The potential for this breakthrough treatment is enormous in reducing the toll of mental illness on patients, their families and society, according to the review.

Unlike electroshock therapy (ECT), which stimulates the entire brain, DBS stimulates specific parts of the brain. DBS is thought to be functionally equivalent to creating a lesion on the brain, but with the advantage of being adjustable and reversible.

"It is like implanting a pacemaker for the brain," says Dr. Lee. The patient is awake during deep brain stimulation surgery while a neurosurgeon implants the electrodes. Patients are able to give immediate feedback. Additionally, patients do not feel any pain during the implantation procedure since the brain is without pain receptors.

In the developed world, major depression is second only to cardiovascular disease in premature mortality and time lived with disability according to the review. In persons aged 15 to 44 years, depression is the most disabling medical illness in the United States. The prevalence of major depression, known to be a chronic and relapsing illness, is approximately 17 percent, affecting almost 1 in 5 persons.

Medications and psychiatric therapy can effectively treat many patients with major depression; however, up to 20 percent of these patients fail to respond to these non-surgical therapeutic interventions.

"DBS is not a miracle cure and should not be used to treat all depression," says Dr. Lee. "It should be reserved for those patients who have treatment-resistant depression and approved by a multi-disciplinary team." Ongoing advances in DBS technologies represent an important new field that could greatly advance the understanding of psychiatric neurobiology, according to the review.


'/>"/>

Contact: John Murphy
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
2. OpusClinicalSuite(R) Achieves 08 CCHIT Certification as Inpatient EHR
3. Clinical Study Data Indicates that Celliant Reduces Pain
4. DaVita Celebrates the Opening of Its 1,500th Outpatient Kidney Care Clinic in the United States
5. Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery
6. MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009
7. Heritage Summit HealthCare Inc. Contracts with Mayo Clinic for Workers Compensation Care
8. MinuteClinic Becomes Participating Provider in All CareFirst BlueCross BlueShield Plans
9. Living Cell Technologies Diabetes Clinical Trial Authorized by New Zealand Government
10. Lifeclinic Teams Up With Trucking Industry to Promote Health and Wellness to Over-the-Road Professionals
11. Caregivers at Alameda County Clinic to Strike Over Bad-Faith Bargaining by Clinic Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... billing and coding services, and Deyta Analytics, recently announced the recipients of the ... level of quality as measured from the caregiver’s point of view. The official ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions ... use of Microsoft Dynamics GP for one their long-term care clients. Working together ... Dynamics GP with key clinical management systems, and delivered a fully integrated accounting ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society ... year, reproductive endocrinologists are required to report in vitro fertilization (IVF) ... dedicated to the practice of assisted reproductive technologies in the United States. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... BC and AD, saying it is time to set the record straight. Traditionally, BC ... this simply cannot possibly be true and offers explanation. , “To start with, the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
Breaking Medicine Technology: